U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C21H21NO2S
Molecular Weight 351.462
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TAZAROTENE

SMILES

CCOC(=O)C1=CC=C(N=C1)C#CC2=CC3=C(SCCC3(C)C)C=C2

InChI

InChIKey=OGQICQVSFDPSEI-UHFFFAOYSA-N
InChI=1S/C21H21NO2S/c1-4-24-20(23)16-7-9-17(22-14-16)8-5-15-6-10-19-18(13-15)21(2,3)11-12-25-19/h6-7,9-10,13-14H,4,11-12H2,1-3H3

HIDE SMILES / InChI
Molecular Formula C21H21NO2S
Molecular Weight 351.462
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020600s008lbl.pdf

Tazarotene a novel acetylenic retinoid is known to be effective in the topical treatment of psoriasis and acne. Tazarotene is rapidly and completely metabolized to its active metabolite tazarotenic acid. The exact mechanism of action of tazarotenic acid in the treatment of psoriasis and acne is not clearly defined. However, it is thought that the selective interaction of tazarotenic acid with the retinoic acid receptor (RAR) family (RARα, RARβ, and RARγ) and the subsequent induction of both positive and negative gene regulatory effects may be involved.

Originator

Approval Year

1997
172
Targets

Targets

Primary TargetPharmacologyConditionPotency
Agonist
2678
Agonist
2678
Agonist
2678
Agonist
2678
 40.0 nM [EC50]
Agonist
2678
 0.8 nM [EC50]
Agonist
2678
 63.0 nM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
TAZORAC

Approved Use

TAZORAC® (tazarotene) Gel 0.05% and 0.1% are indicated for the topical treatment of patients with stable plaque psoriasis of up to 20% body surface area involvement. TAZORAC® (tazarotene) Gel 0.1% is also indicated for the topical treatment of patients with facial acne vulgaris of mild to moderate severity.

Launch Date

2000
Primary
Approved
8429
TAZORAC

Approved Use

TAZORAC® (tazarotene) Gel 0.05% and 0.1% are indicated for the topical treatment of patients with stable plaque psoriasis of up to 20% body surface area involvement. TAZORAC® (tazarotene) Gel 0.1% is also indicated for the topical treatment of patients with facial acne vulgaris of mild to moderate severity.

Launch Date

2000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
5.44 pg/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/31641413
5 mg single, topical
dose: 5 mg
route of administration: Topical
experiment type: SINGLE
co-administered:
TAZAROTENE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
105.72 pg × h/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/31641413
5 mg single, topical
dose: 5 mg
route of administration: Topical
experiment type: SINGLE
co-administered:
TAZAROTENE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
33.6 mg 1 times / day multiple, oral
Highest studied dose
Dose: 33.6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 33.6 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/12942109
Page: p.812
unhealthy, 39 – 72
n = 6
Health Status: unhealthy
Condition: Advanced cancer
Age Group: 39 – 72
Sex: M+F
Population Size: 6
Sources:
https://pubmed.ncbi.nlm.nih.gov/12942109
Page: p.812
DLT: Hypercalcaemia, Hypertriglyceridaemia...
Dose limiting toxicities:
Hypercalcaemia (grade 3, 17%)
Hypertriglyceridaemia (grade 4, 17%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/12942109
Page: p.812
25.2 mg 1 times / day multiple, oral
MTD
Dose: 25.2 mg, 1 times / day
Route: oral
Route: multiple
Dose: 25.2 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/12942109
Page: p.812
unhealthy, 39 – 72
n = 6
Health Status: unhealthy
Condition: Advanced cancer
Age Group: 39 – 72
Sex: M+F
Population Size: 6
Sources:
https://pubmed.ncbi.nlm.nih.gov/12942109
Page: p.812
DLT: Musculoskeletal pain...
Dose limiting toxicities:
Musculoskeletal pain (grade 3, 17%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/12942109
Page: p.812
0.1 % 1 times / day multiple, topical
Recommended
Dose: 0.1 %, 1 times / day
Route: topical
Route: multiple
Dose: 0.1 %, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020600s010lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Plaque psoriasis|Acne vulgaris
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020600s010lbl.pdf
Page: p.1
Disc. AE: Disorder fetal, Skin irritation...
AEs leading to
discontinuation/dose reduction:
Disorder fetal
Skin irritation
Pruritus
Burning skin
Skin red
Skin peeling
Photosensitivity
Sunburn
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020600s010lbl.pdf
Page: p.1
AEs

AEs

AESignificanceDosePopulation
Hypercalcaemia grade 3, 17%
DLT
33.6 mg 1 times / day multiple, oral
Highest studied dose
Dose: 33.6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 33.6 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/12942109
Page: p.812
unhealthy, 39 – 72
n = 6
Health Status: unhealthy
Condition: Advanced cancer
Age Group: 39 – 72
Sex: M+F
Population Size: 6
Sources:
https://pubmed.ncbi.nlm.nih.gov/12942109
Page: p.812
Hypertriglyceridaemia grade 4, 17%
DLT
33.6 mg 1 times / day multiple, oral
Highest studied dose
Dose: 33.6 mg, 1 times / day
Route: oral
Route: multiple
Dose: 33.6 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/12942109
Page: p.812
unhealthy, 39 – 72
n = 6
Health Status: unhealthy
Condition: Advanced cancer
Age Group: 39 – 72
Sex: M+F
Population Size: 6
Sources:
https://pubmed.ncbi.nlm.nih.gov/12942109
Page: p.812
Musculoskeletal pain grade 3, 17%
DLT
25.2 mg 1 times / day multiple, oral
MTD
Dose: 25.2 mg, 1 times / day
Route: oral
Route: multiple
Dose: 25.2 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/12942109
Page: p.812
unhealthy, 39 – 72
n = 6
Health Status: unhealthy
Condition: Advanced cancer
Age Group: 39 – 72
Sex: M+F
Population Size: 6
Sources:
https://pubmed.ncbi.nlm.nih.gov/12942109
Page: p.812
Burning skin Disc. AE
0.1 % 1 times / day multiple, topical
Recommended
Dose: 0.1 %, 1 times / day
Route: topical
Route: multiple
Dose: 0.1 %, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020600s010lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Plaque psoriasis|Acne vulgaris
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020600s010lbl.pdf
Page: p.1
Disorder fetal Disc. AE
0.1 % 1 times / day multiple, topical
Recommended
Dose: 0.1 %, 1 times / day
Route: topical
Route: multiple
Dose: 0.1 %, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020600s010lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Plaque psoriasis|Acne vulgaris
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020600s010lbl.pdf
Page: p.1
Photosensitivity Disc. AE
0.1 % 1 times / day multiple, topical
Recommended
Dose: 0.1 %, 1 times / day
Route: topical
Route: multiple
Dose: 0.1 %, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020600s010lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Plaque psoriasis|Acne vulgaris
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020600s010lbl.pdf
Page: p.1
Pruritus Disc. AE
0.1 % 1 times / day multiple, topical
Recommended
Dose: 0.1 %, 1 times / day
Route: topical
Route: multiple
Dose: 0.1 %, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020600s010lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Plaque psoriasis|Acne vulgaris
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020600s010lbl.pdf
Page: p.1
Skin irritation Disc. AE
0.1 % 1 times / day multiple, topical
Recommended
Dose: 0.1 %, 1 times / day
Route: topical
Route: multiple
Dose: 0.1 %, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020600s010lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Plaque psoriasis|Acne vulgaris
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020600s010lbl.pdf
Page: p.1
Skin peeling Disc. AE
0.1 % 1 times / day multiple, topical
Recommended
Dose: 0.1 %, 1 times / day
Route: topical
Route: multiple
Dose: 0.1 %, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020600s010lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Plaque psoriasis|Acne vulgaris
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020600s010lbl.pdf
Page: p.1
Skin red Disc. AE
0.1 % 1 times / day multiple, topical
Recommended
Dose: 0.1 %, 1 times / day
Route: topical
Route: multiple
Dose: 0.1 %, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020600s010lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Plaque psoriasis|Acne vulgaris
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020600s010lbl.pdf
Page: p.1
Sunburn Disc. AE
0.1 % 1 times / day multiple, topical
Recommended
Dose: 0.1 %, 1 times / day
Route: topical
Route: multiple
Dose: 0.1 %, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020600s010lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Plaque psoriasis|Acne vulgaris
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020600s010lbl.pdf
Page: p.1
PubMed

PubMed

TitleDatePubMed
Practical management of psoriasis in the elderly: epidemiology, clinical aspects, quality of life, patient education and treatment options.
2002
Refining retinoids with heteroatoms.
2002 Jun
[Immunosuppresive agents, retinoids and new trends in the therapy of psoriasis].
2002 Nov
Questionable techniques for evaluating photodamage.
2002 Nov
Efficacy of 0.1% tazarotene cream for the treatment of photodamage: a 12-month multicenter, randomized trial.
2002 Nov
Retrospective analysis of the treatment of psoriasis of the palms and soles.
2003
Treatment of occupational koilonychia with tazarotene gel.
2003
The rationale for using a topical retinoid for inflammatory acne.
2003
Investigational therapies for psoriasis.
2003 Aug
Wrinkles.
2003 Dec
The efficacy of topical tazarotene monotherapy and combination therapies in psoriasis.
2003 Dec
Characterization of human circulating TIG2 as a ligand for the orphan receptor ChemR23.
2003 Dec 18
Management of acne.
2003 Jan
Tazarotene 0.1% gel for psoriasis of the fingernails and toenails: an open, prospective study.
2003 Jul
The topical treatment of psoriasis.
2003 Mar-Apr
Confluent and reticulated papillomatosis: response to tazarotene.
2003 May
[Medication of the month. Tazarotene 0.05%-0.1% (Zorac)].
2003 Nov
Tazarotene-induced gene 3 is suppressed in basal cell carcinomas and reversed in vivo by tazarotene application.
2003 Oct
Comparison of prognostic factors in patients in phase I trials of cytotoxic drugs vs new noncytotoxic agents.
2003 Oct 6
A phase 1 study of tazarotene in adults with advanced cancer.
2003 Sep 1
Spotlight on adapalene in acne vulgaris.
2004
Tazarotene does not affect the pharmacokinetics and efficacy of a norethindrone/ethinylestradiol oral contraceptive.
2004
Adapalene: a review of its use in the treatment of acne vulgaris.
2004
Tazarotene 0.1% cream for the treatment of photodamage.
2004 Apr
Evidence of increased apoptosis and reduced proliferation in basal cell carcinomas treated with tazarotene.
2004 Apr
Seborrheic keratoses: a study comparing the standard cryosurgery with topical calcipotriene, topical tazarotene, and topical imiquimod.
2004 Apr
Tazarotene 0.1% gel for refractory mycosis fungoides lesions: an open-label pilot study.
2004 Apr
The p73 gene is an anti-tumoral target of the RARbeta/gamma-selective retinoid tazarotene.
2004 Dec
Histological effects of tazarotene 0.1% cream vs. vehicle on photodamaged skin: a 6-month, multicentre, double-blind, randomized, vehicle-controlled study in patients with photodamaged facial skin.
2004 Dec
A retinoic acid receptor beta/gamma-selective prodrug (tazarotene) plus a retinoid X receptor ligand induces extracellular signal-regulated kinase activation, retinoblastoma hypophosphorylation, G0 arrest, and cell differentiation.
2004 Dec
Treatment of lentigo maligna with tazarotene 0.1% gel.
2004 Jan
[Prescribe topical treatments for psoriasis].
2004 Jan 15
Topical treatment of basal cell carcinoma with tazarotene: a clinicopathological study on a large series of cases.
2004 Jul
Questions & answers. Of all the treatments that promise to improve the appearance of aging skin, which ones have been medically proven to actually work?
2004 Jul
Topical tazarotene chemoprevention reduces Basal cell carcinoma number and size in Ptch1+/- mice exposed to ultraviolet or ionizing radiation.
2004 Jul 1
Elephantiasis nostrum verrucosa of the abdomen: clinical results with tazarotene.
2004 Jul-Aug
Tazarotene 0.1% cream versus tretinoin 0.05% emollient cream in the treatment of photodamaged facial skin: a multicenter, double-blind, randomized, parallel-group study.
2004 Jun
Established treatments of psoriasis.
2004 Jun
Topical retinoid and antibiotic combination therapy for acne management.
2004 Mar-Apr
Oral tazarotene and oral pimecrolimus: novel oral therapies in development for psoriasis.
2004 Mar-Apr
Current management strategies for cutaneous T-cell lymphoma.
2004 May-Jun
Tazarotene: therapeutic strategies in the treatment of psoriasis, acne and photoaging.
2004 May-Jun
Phase II trial of the antiangiogenic agent IM862 in metastatic renal cell carcinoma.
2004 Nov 1
Topical tazarotene in acne vulgaris: treatment approaches.
2004 Oct
Meta-analysis of topical tazarotene in the treatment of mild to moderate acne.
2004 Oct
Topical tazarotene: The BEST (balancing efficacy, speed, and tolerability) in acne trial.
2004 Oct
Topical retinoids in the management of acne: the best path to clear results.
2004 Oct
Retinoid therapy for psoriasis.
2004 Oct
Keratosis punctata palmoplantaris controlled with topical retinoids: a case report and review of the literature.
2004 Sep
Comparison of topical retinoids in the treatment of acne.
2004 Sep-Oct
Patents

Patents

05348972
2
20050155090
2

Sample Use Guides

In Vivo Use Guide
For psoriasis: It is recommended that treatment start with TAZORAC (Tazarotene) 0.05% Gel, with strength increased to 0.1% if tolerated and medically indicated. Apply TAZORAC® Gel once a day, in the evening, to psoriatic lesions, using enough (2 mg/cm2) to cover only the lesion with a thin film to no more than 20% of body surface area. If a bath or shower is taken prior to application, the skin should be dry before applying the gel. If emollients are used, they should be applied at least an hour before application of TAZORAC® Gel.
Route of Administration: Topical
In Vitro Use Guide
Tazarotene treatment caused a dose-dependent reduction in cell proliferation in BCC cell line ASZ001 cells (the strongest effect on cell proliferation was at 10 umol/L)
Substance Class Chemical
Created
by admin
on Sat Dec 16 17:04:43 GMT 2023
Edited
by admin
on Sat Dec 16 17:04:43 GMT 2023
Record UNII
81BDR9Y8PS
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TAZAROTENE
INCI   INN   JAN   MART.   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
INCI   USAN   INN  
Official Name English
AVAGE
Brand Name English
IDP-123
Code English
TAZAROTENE [USAN]
Common Name English
TAZAROTENE [MI]
Common Name English
Tazarotene [WHO-DD]
Common Name English
IDP-118 COMPONENT TAZAROTENE
Common Name English
TAZAROTENE [JAN]
Common Name English
TAZAROTENE [VANDF]
Common Name English
tazarotene [INN]
Common Name English
TAZORAC
Brand Name English
ARAZLO
Brand Name English
Ethyl 6-[(4,4-dimethylthiochroman-6-yl)ethynyl]nicotinate
Systematic Name English
TAZAROTENE [ORANGE BOOK]
Common Name English
AGN-190168
Code English
TAZAROTENE COMPONENT OF DUOBRII
Brand Name English
AGN190168
Code English
DUOBRII COMPONENT TAZAROTENE
Brand Name English
3-PYRIDINECARBOXYLIC ACID, 6-((3,4-DIHYDRO-4,4-DIMETHYL-2H-1-BENZOTHIOPYRAN-6-YL)ETHYNYL)-, ETHYL ESTER
Common Name English
TAZAROTENE [MART.]
Common Name English
TAZAROTENE [INCI]
Common Name English
Classification Tree Code System Code
NDF-RT N0000007700
Created by admin on Sat Dec 16 17:04:43 GMT 2023 , Edited by admin on Sat Dec 16 17:04:43 GMT 2023
NDF-RT N0000007700
Created by admin on Sat Dec 16 17:04:43 GMT 2023 , Edited by admin on Sat Dec 16 17:04:43 GMT 2023
NDF-RT N0000007700
Created by admin on Sat Dec 16 17:04:43 GMT 2023 , Edited by admin on Sat Dec 16 17:04:43 GMT 2023
WHO-ATC D05AX05
Created by admin on Sat Dec 16 17:04:43 GMT 2023 , Edited by admin on Sat Dec 16 17:04:43 GMT 2023
WHO-VATC QD05AX05
Created by admin on Sat Dec 16 17:04:43 GMT 2023 , Edited by admin on Sat Dec 16 17:04:43 GMT 2023
NCI_THESAURUS C804
Created by admin on Sat Dec 16 17:04:43 GMT 2023 , Edited by admin on Sat Dec 16 17:04:43 GMT 2023
NDF-RT N0000007700
Created by admin on Sat Dec 16 17:04:43 GMT 2023 , Edited by admin on Sat Dec 16 17:04:43 GMT 2023
EU-Orphan Drug EU/3/06/423
Created by admin on Sat Dec 16 17:04:43 GMT 2023 , Edited by admin on Sat Dec 16 17:04:43 GMT 2023
NDF-RT N0000175607
Created by admin on Sat Dec 16 17:04:43 GMT 2023 , Edited by admin on Sat Dec 16 17:04:43 GMT 2023
NDF-RT N0000007700
Created by admin on Sat Dec 16 17:04:43 GMT 2023 , Edited by admin on Sat Dec 16 17:04:43 GMT 2023
Code System Code Type Description
USAN
FF-57
Created by admin on Sat Dec 16 17:04:43 GMT 2023 , Edited by admin on Sat Dec 16 17:04:43 GMT 2023
PRIMARY
MESH
C086827
Created by admin on Sat Dec 16 17:04:43 GMT 2023 , Edited by admin on Sat Dec 16 17:04:43 GMT 2023
PRIMARY
PUBCHEM
5381
Created by admin on Sat Dec 16 17:04:43 GMT 2023 , Edited by admin on Sat Dec 16 17:04:43 GMT 2023
PRIMARY
CAS
118292-40-3
Created by admin on Sat Dec 16 17:04:43 GMT 2023 , Edited by admin on Sat Dec 16 17:04:43 GMT 2023
PRIMARY
CHEBI
32184
Created by admin on Sat Dec 16 17:04:43 GMT 2023 , Edited by admin on Sat Dec 16 17:04:43 GMT 2023
PRIMARY
RXCUI
83947
Created by admin on Sat Dec 16 17:04:43 GMT 2023 , Edited by admin on Sat Dec 16 17:04:43 GMT 2023
PRIMARY RxNorm
DRUG BANK
DB00799
Created by admin on Sat Dec 16 17:04:43 GMT 2023 , Edited by admin on Sat Dec 16 17:04:43 GMT 2023
PRIMARY
WIKIPEDIA
TAZAROTENE
Created by admin on Sat Dec 16 17:04:43 GMT 2023 , Edited by admin on Sat Dec 16 17:04:43 GMT 2023
PRIMARY
EPA CompTox
DTXSID5046691
Created by admin on Sat Dec 16 17:04:43 GMT 2023 , Edited by admin on Sat Dec 16 17:04:43 GMT 2023
PRIMARY
MERCK INDEX
m10488
Created by admin on Sat Dec 16 17:04:43 GMT 2023 , Edited by admin on Sat Dec 16 17:04:43 GMT 2023
PRIMARY Merck Index
FDA UNII
81BDR9Y8PS
Created by admin on Sat Dec 16 17:04:43 GMT 2023 , Edited by admin on Sat Dec 16 17:04:43 GMT 2023
PRIMARY
ChEMBL
CHEMBL1657
Created by admin on Sat Dec 16 17:04:43 GMT 2023 , Edited by admin on Sat Dec 16 17:04:43 GMT 2023
PRIMARY
LACTMED
Tazarotene
Created by admin on Sat Dec 16 17:04:43 GMT 2023 , Edited by admin on Sat Dec 16 17:04:43 GMT 2023
PRIMARY
DRUG CENTRAL
2571
Created by admin on Sat Dec 16 17:04:43 GMT 2023 , Edited by admin on Sat Dec 16 17:04:43 GMT 2023
PRIMARY
DAILYMED
81BDR9Y8PS
Created by admin on Sat Dec 16 17:04:43 GMT 2023 , Edited by admin on Sat Dec 16 17:04:43 GMT 2023
PRIMARY
EVMPD
SUB10844MIG
Created by admin on Sat Dec 16 17:04:43 GMT 2023 , Edited by admin on Sat Dec 16 17:04:43 GMT 2023
PRIMARY
IUPHAR
6952
Created by admin on Sat Dec 16 17:04:43 GMT 2023 , Edited by admin on Sat Dec 16 17:04:43 GMT 2023
PRIMARY
INN
7328
Created by admin on Sat Dec 16 17:04:43 GMT 2023 , Edited by admin on Sat Dec 16 17:04:43 GMT 2023
PRIMARY
SMS_ID
100000082411
Created by admin on Sat Dec 16 17:04:43 GMT 2023 , Edited by admin on Sat Dec 16 17:04:43 GMT 2023
PRIMARY
NCI_THESAURUS
C29487
Created by admin on Sat Dec 16 17:04:43 GMT 2023 , Edited by admin on Sat Dec 16 17:04:43 GMT 2023
PRIMARY
Related Record Type Details
Structure of TAZAROTENIC ACID SULFOXIDE
METABOLITE INACTIVE -> PARENT
FECAL; URINE
Structure of TAZAROTENIC ACID SULFONE
METABOLITE INACTIVE -> PARENT
FECAL; URINE
Structure of TAZAROTENIC ACID
METABOLITE ACTIVE -> PRODRUG
Related Record Type Details
Structure of TAZAROTENIC ACID
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966